Elegant antibody nanoparticles override immunological tolerance of tumors
Immune checkpoint blockade (ICB) therapy using the antibody that combats the programmed cell death ligand 1 (PD-L1) shows great potential and is causing a revolution in clinical cancer management. Unfortunately, only a subset ...
Jul 12, 2019
0
126